Literature DB >> 9345199

Conservative treatment of hemarthrosis for prevention of hemophilic synovitis.

W J Ribbans1, P Giangrande, K Beeton.   

Abstract

Acute hemarthroses are probably the most frequent type of bleeding in the patient with hemophilia. Delayed and/or inadequate treatment can trigger a series of pathologic changes within the joint leading to a painful and disabling arthropathy. Despite the advent of prophylactic treatment with factor concentrates, the majority of patients in the world have no access to even on demand factor replacement. Care for all patients involves a team approach led by the hematologist but including input from orthopaedic surgeons and physiotherapists. Optimal treatment involves a combination of factor replacement, rest, ice, and supervised rehabilitation. In certain cases, joint aspiration may be considered. In developing countries, where factor concentrates are in short supply, such bleeding episodes usually are treated by physical means alone or with the addition of cryoprecipitate or fresh frozen plasma. After successful resolution of such episodes by whatever means, the events leading to the bleeding episode and its subsequent management should be considered within the setting of the treating unit. Such debriefings should aim to provide counsel regarding any appropriate lifestyle modifications and, where necessary, treatment should be arranged to minimize the risk of additional episodes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345199

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Traumatic Hemarthrosis of the Knee Secondary to Hemophilia A in a Collegiate Soccer Player: A Case Report.

Authors:  Kelly A Fiala; Sandra J Hoffmann; Donna M Ritenour
Journal:  J Athl Train       Date:  2002-09       Impact factor: 2.860

2.  A prospective series of musculoskeletal system rehabilitation of arthropathic joints in young male hemophilic patients.

Authors:  Eda Gurcay; Emel Eksioglu; Ustun Ezer; Banu Cakir; Aytul Cakci
Journal:  Rheumatol Int       Date:  2007-10-18       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.